Description

PT-141 10MG

We provide PT-141 as a 10MG synthetic cyclic heptapeptide research compound with a stated 99.1% purity. Furthermore, PT-141 is the research name associated with bremelanotide, a cyclic analog of α-melanocyte-stimulating hormone (α-MSH) that interacts with melanocortin receptors. Consequently, researchers have investigated its molecular relationship with MC1R, MC3R, MC4R, and other melanocortin receptor subtypes, particularly within central nervous system and neuroendocrine research.

Key Attributes

• Brand: AvigenLab
• Product Name: PT-141
• Quantity: 10MG
• Stated Purity: 99.1%
• Molecular Type: Synthetic Cyclic Heptapeptide
• Alternative Name: Bremelanotide
• Sequence: Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys
• Sequence Length: 7 Amino Acids
• Molecular Formula: C₅₀H₆₈N₁₄O₁₀
• Molecular Weight: 1,025.2 g/mol
• CAS Number: 189691-06-3
• Product Format: Vial
• Classification: Research Use Only
• Human Use: Not For Human Use

Product Overview

We provide PT-141 for research involving melanocortin receptor signaling, neuroendocrine pathways, central melanocortin biology, receptor-ligand interactions, and related cellular signaling mechanisms. Moreover, structural research has directly examined bremelanotide bound to MC4R, providing detailed insight into peptide recognition and receptor activation.

Additionally, the FDA describes bremelanotide as a melanocortin receptor agonist with activity across several receptor subtypes, including MC1R, MC3R, and MC4R. Therefore, the compound provides a defined molecular model for investigating how melanocortin receptor activation influences downstream signaling.

Explore additional research materials through our Online Store.

Product Identification

We identify PT-141 through its 10MG quantity, synthetic cyclic heptapeptide structure, stated 99.1% purity, and vial presentation. PubChem identifies bremelanotide as an oligopeptide with the sequence XDHFRWK, corresponding to Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys, and reports a molecular weight of 1,025.2 g/mol for the free-base form.

Accordingly, the molecular identity, sequence, quantity, purity designation, and physical presentation provide clear reference points for laboratory documentation and inventory management.

Product Category

We classify PT-141 within our research peptide collection for melanocortin, neuroendocrine, receptor-signaling, and central nervous system investigations. Furthermore, melanocortin receptors participate in diverse biological processes, including energy homeostasis and neuroendocrine signaling.

Moreover, MC4R research has established the receptor as an important G-protein-coupled receptor involved in central regulation of energy balance. Consequently, compounds that interact with this receptor provide useful molecular tools for investigating receptor activation, ligand recognition, and downstream signaling.

Scientific Characteristics

The molecular structure of PT-141 contains seven amino acids arranged within a cyclic peptide framework. In particular, PubChem records the sequence as XDHFRWK and identifies bremelanotide as C₅₀H₆₈N₁₄O₁₀ with a molecular weight of 1,025.2 g/mol.

Furthermore, the cyclic structure contributes to the compound’s distinct molecular configuration and receptor-binding characteristics. Meanwhile, structural studies have shown how bremelanotide occupies the MC4R binding site and interacts with receptor residues involved in activation. Therefore, researchers can investigate both peptide structure and receptor function using a defined molecular system.

Research Applications

We position PT-141 for research involving melanocortin receptor signaling, MC4R activity, MC3R biology, central neuroendocrine pathways, cAMP-associated signaling, ligand-receptor interactions, and energy-homeostasis research.

Additionally, research has demonstrated that melanocortin receptors operate as G-protein-coupled receptors capable of stimulating intracellular signaling pathways. Likewise, studies examining MC3R and MC4R have characterized receptor-dependent cAMP responses following stimulation with melanocortin analogs.

Furthermore, bremelanotide research has examined central nervous system mechanisms involving MC4R-expressing neurons and neurotransmitter pathways. Nevertheless, some proposed downstream neurobiological mechanisms remain areas of investigation rather than established explanations for every observed response.

Product Configuration

We provide PT-141 in a 10MG vial carrying a stated 99.1% purity designation. Accordingly, the defined quantity, peptide identity, purity specification, and vial presentation establish straightforward reference points for laboratory inventory.

Moreover, the individual-peptide configuration distinguishes this material from combination products and other melanocortin-related research formulations. Consequently, researchers can organize the product according to its specific molecular identity, quantity, purity, and physical format.

Product Features

The primary features include a 10MG quantity, 99.1% stated purity, cyclic heptapeptide structure, and clearly defined research-use presentation. Additionally, our product label communicates Not For Human Use | Research Use Only.

Furthermore, the scientific profile encompasses melanocortin receptor activity, MC4R structural biology, central melanocortin signaling, and neuroendocrine research. As a result, the material provides a defined molecular subject for investigating receptor activation and downstream cellular responses.

Product Specifications

The molecular formula, molecular weight, sequence, and CAS number correspond with the free-base bremelanotide identity recorded by PubChem and FDA substance records.

Intended Research Context

We identify the material as Research Use Only and Not For Human Use. Accordingly, our documentation focuses on laboratory investigation rather than therapeutic or consumer applications.

In particular, researchers can examine the compound within experimental systems involving melanocortin receptors, MC4R activation, receptor-ligand recognition, central melanocortin pathways, and cellular signaling. Furthermore, structural studies have provided high-resolution information about bremelanotide interaction with MC4R and the resulting receptor activation process.

Nevertheless, experimental receptor activity does not automatically establish equivalent outcomes across different biological systems. Therefore, researchers should evaluate observations according to the relevant model, methodology, formulation, and experimental endpoint.

Packaging Information

We present PT-141 in a clearly labeled 10MG vial featuring our AvigenLab product presentation. The packaging displays the 10MG quantity, communicates the stated 99.1% Purity, and identifies the material as Not For Human Use | Research Use Only.

Additionally, the vial format provides straightforward identification within our research catalog. You can also explore related research materials through our Catalog.

Regulatory Information

We classify the product as Research Use Only and maintain the Not For Human Use designation throughout our product documentation. Accordingly, regulatory information concerning pharmaceutical bremelanotide formulations does not constitute regulatory approval for this specific AvigenLab research presentation.

Moreover, the FDA identifies bremelanotide as a melanocortin receptor agonist and documents activity across several melanocortin receptor subtypes. However, those regulatory findings concern an approved pharmaceutical formulation rather than this 10MG research product.

Consequently, we focus our documentation on molecular identity, research relevance, product specifications, and published scientific evidence without presenting experimental observations as established therapeutic outcomes.

Storage and Handling

We recommend following the storage and handling conditions specified in the applicable AvigenLab product documentation. Furthermore, researchers should maintain appropriate laboratory handling practices and follow product-specific documentation.

Because peptide stability can depend on formulation, packaging, environmental exposure, and other product-specific variables, we avoid assigning unsupported storage parameters. Consequently, this approach supports consistent laboratory management without introducing assumptions about conditions that may vary between formulations.

Market Availability

Our 10MG presentation provides a defined research peptide configuration within our collection. The quantity, stated purity, molecular identity, cyclic structure, vial format, and Research Use Only designation create clear reference points for laboratory inventory.

Moreover, bremelanotide has an extensive scientific research history within melanocortin receptor biology. Likewise, researchers have examined its interaction with MC4R through both pharmacological and structural approaches, providing a substantial foundation for continued receptor and neuroendocrine research.

Product Reference

Our PT-141 10MG presentation provides a defined synthetic cyclic heptapeptide carrying a stated 99.1% purity designation. We document the material according to its molecular sequence, structural characteristics, receptor research profile, vial configuration, and Research Use Only classification.

Consequently, the product provides researchers with a clearly identified material for investigating melanocortin receptor activity, MC4R signaling, central neuroendocrine pathways, ligand-receptor interactions, and related cellular mechanisms. Furthermore, structural research involving bremelanotide and MC4R provides valuable molecular insight into how cyclic peptide agonists interact with and activate melanocortin receptors.

For additional product information, researchers can also visit our Shop.